Morgan Stanley lowered the firm’s price target on Baxter (BAX) to $27 from $28 and keeps an Underweight rating on the shares. The firm continues to like the MedTech industry setup into Q2 on relative stability in procedure volumes and hospital capital expenditures across the space, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX:
- Baxter price target lowered to $32 from $34 at Citi
- Baxter appoints Andrew Hider as CEO
- Baxter International Appoints Andrew Hider as New CEO
- Baxter International Amends Credit and Loan Agreements
- Baxter International Poised for Growth: Buy Rating Affirmed Amid Strategic Initiatives and Promising Outlook